ANALYTICAL TECHNIQUES FOR DETERMINATION OF MIRABEGRON FROM BULK, PHARMACEUTICAL FORMULATION, AND BIOLOGICAL MATRICES: A CRITICAL REVIEW

SANJAY DINKAR SAWANT; SHITAL DIGAMBAR GODSE

doi:10.22159/ijap.2024v16i3.50267

Authors

SANJAY DINKAR SAWANT Department of Pharmaceutical Chemistry, Sinhgad Technical Education Society’s, Smt. Kashibai Navale College of Pharmacy, Pune, Maharashtra, India
SHITAL DIGAMBAR GODSE Department of Pharmaceutical Chemistry, Sinhgad Technical Education Society’s, Smt. Kashibai Navale College of Pharmacy, Pune, Maharashtra, India

DOI:

https://doi.org/10.22159/ijap.2024v16i3.50267

Keywords:

Mirabegron, Analytical techniques, Chromatography, Spectroscopy

Abstract

Mirabegron is a beta-3 adrenergic receptor agonist and is specified for the treatment of overactive Bladder. This review covers analytical methods aimed at the identification and quantification of mirabegron in bulk, commercial dosage forms, and Biological fluids. Using various techniques such as UV-spectroscopy, spectro-fluorimetry, planer chromatography, High Performance-Thin Layer Chromatography (HPTLC), HPLC, High-Performance Liquid Chromatography-MS/MS (HPLC-MS/MS), Ultra-Pressure Liquid Chromatography-MS/MS (UPLC-MS/MS), and capillary electrophoresis. HPLC is the most used analytical technique for the identification and quantification of mirabegron in bulk and commercial dosage forms.

Downloads

Download data is not yet available.

References

Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003 May;20(6):327-36. doi: 10.1007/s00345-002-0301-4, PMID 12811491.

Himashree G, Banerjee PK, Selvamurthy WW. Sleep and performance-recent trends. Indian J Physiol Pharmacol. 2002 Jan;46(1):6-24. PMID 12024958.

Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and Bladder outlet obstruction. BJU Int. 2011 Oct;108(7):1132-8. doi: 10.1111/j.1464-410X.2010.09993.x, PMID 21231991.

Sacco E, Bientinesi R. Mirabegron: a review of recent data and its prospects in the management of overactive bladder. Ther Adv Urol. 2012 Dec;4(6):315-24. doi: 10.1177/1756287212457114, PMID 23205058, PMCID PMC3491758.

Yamaguchi O. Beta3-adrenoceptors in human detrusor muscle. Urology. 2002 May;59(5)Suppl 1:25-9. doi: 10.1016/s0090-4295(01)01635-1, PMID 12007519.

El Helou E, Labaki C, Chebel R, El Helou J, Abi Tayeh G, Jalkh G. The use of mirabegron in neurogenic Bladder: a systematic review. World J Urol. 2020 Oct;38(10):2435-42. doi: 10.1007/s00345-019-03040-x, PMID 31802206.

Shin JH, Choo MS. Effectiveness and persistence of mirabegron as a first-line treatment in patients with overactive bladder in real-life practice. Low Urin Tract Symptoms. 2019 May;11(3):151-7. doi: 10.1111/luts.12253, PMID 30623583.

Nambiar AK, Bosch R, Cruz F, Lemack GE, Thiruchelvam N, Tubaro A. EAU guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol. 2018 Apr;73(4):596-609. doi: 10.1016/j.eururo.2017.12.031, PMID 29398262.

Quintana Mendoza JH, Henao JA, Aparicio AP, Romero Bohorquez AR. X-ray powder diffraction data and characterization of mirabegron. Powder Diffr. 2017;32(4):290-4. doi: 10.1017/S0885715617001129.

Allison SJ, Gibson W. Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience. Ther Adv Urol. 2018 Sep 26;10(12):411-9. doi: 10.1177/1756287218801282, PMID 30574201, PMCID PMC6295783.

Satheeshkumar N, Shantikumar S, Srinivas R. Pioglitazone: a review of analytical methods. J Pharm Anal. 2014 Oct;4(5):295-302. doi: 10.1016/j.jpha.2014.02.002. PMID 29403893, PMCID PMC5761212.

Warren K, Burden H, Abrams P. Mirabegron in overactive bladder patients: efficacy review and update on drug safety. Ther Adv Drug Saf. 2016 Oct;7(5):204-16. doi: 10.1177/2042098616659412, PMID 27695622, PMCID PMC5014049.

Sacco E, Bientinesi R. Mirabegron: a review of recent data and its prospects in the management of overactive bladder. Ther Adv Urol. 2012 Dec;4(6):315-24. doi: 10.1177/1756287212457114, PMID 23205058, PMCID PMC3491758.

Nageswara R, Madhuri D, Siva L, Rani K, Tejaswini P. Development and validation of a derivative spectrophotometric method for estimation of mirabegron in bulk and tablet dosage form. World J Pharm Res. 2017;6(14):760-7. doi: 10.20959/wjpr201714-9967.

Roopa Kothathi Papanna, Gowda JBK, Nagaraja P. An experimental design approach for optimization of spectrophotometric estimation of mirabegron in bulk and pharmaceutical formulations. J Anal Chem. 2018;73(9):884-93. doi: 10.1134/S1061934818090095.

Babu GR. Stability-indicating simultaneous estimation of vildagliptin and mirabegron in bulk and pharmaceutical dosage form by using UV spectroscopy. WJPPS. 2017:912-25. doi: 10.20959/WJPPS20175-9086.

Yadav PN, Chhalotiya UK, Patel KM, Jinal N. Tandel ” Quantification of A β adrenergic receptor drug mirabegron by stability indicating LC method and UV–visible spectroscopic method in bulk and pharmaceutical dosage form.” Chemical Methodologies. 2020;4(3):340-58. doi: 10.33945/SAMI/CHEMM/2020.3.11.

Chatwal G, Anand S. Instrumental methods of chemical analysis. Vol. 2. Himalaya Publishing House; 2010. p. 617-2.623.

Paisa G. Analytical method development and validation of mirabegron HCl aripiprazole by HPLC and UPLC. Vols. 682-685; 2018. Available from: http://hdl.handle.net/20.500.14146/4108.

Ramazani A, Rezaei M. RP-HPLC method development and validation for the quantitative estimation of mirabegron in extended-release tablets. J Med Chem Sci. 2018;1(2):26-44.

Mounika B, Srikanth L, Venkatesha A. Determination and validation of RP-HPLC method for the estimation of mirabegron in tablet dosage form. Int J Curr Pharm Sci. 2017;9(5):140-51. doi: 10.22159/ijcpr.2017v9i5.22158, doi: 10.22159/ijcpr.2017v9i5.22158.

Suryawanshi R, Shaikh S, Patil S. RP-HPLC method development and validation for the estimation of mirabegron in bulk and dosage form. J Drug Delivery Ther. 2020;10(1):31-8. doi: 10.22270/jddt.v10i1.3829.

Patel J. Development and validation of UV and RP-HPLC methods for simultaneous estimation of mirabegron and solifenacin succinate in their pharmaceutical dosage form. IJPBMS. 2022;02(8):223-32. doi: 10.47191/ijpbms/v2-i8-01.

Spandana R, Nageswara Rao R, Sanker Reddy LS. Analytical method development and validation for the estimation of mirabegron in bulk and pharmaceutical dosage form by RP-HPLC. Indo Am J Pharm Res. 2016;6(11):6880-7.

Jyothsna M, Rayees Ahmed Md, Ramesh T. Method development and validation of mirabegron in bulk drug and pharmaceutical dosage form. J Pharm Biol Sci, (IOSR-JPBS). 2018;13(1):78-83. doi: 10.9790/3008-1301037883.

Zhou F, Zhou Y, Zou Q, Sun L, Wei P. Liquid chromatographic separation and thermodynamic investigation of mirabegron enantiomers on a Chiralpak AY-H column. J Chromatogr Sci. 2015 Sep;53(8):1361-5. doi: 10.1093/chromsci/bmv025, PMID 25824570.

Swartz ME. UPLC™: an introduction and review. J Liq Chromatogr Relat Technol. 2005;28(7-8):1253-63. doi: 10.1081/JLC-200053046.

Pentapuri Saipriya MSK. Develop a new RP-UPLC method for estimation of mirabegron in pharmaceutical dosage forms with forced degradation studies. J Glob Trends Pharm Sci. 2018;9(3):5692-701.

Chen L, Zhang Y. Determination of mirabegron in rat plasma by UPLC-MS/MS after oral and intravenous administration. Rev Assoc Med Bras. 2019;65(2):141-8. doi: 10.1590/1806-9282.65.2.141, PMID 30892436.

Kalariya PD, Sharma M, Garg P, Thota JR, Ragampeta S, Talluri MVNK. Characterization of stress degradation products of mirabegron using UPLC-QTOF-MS/MS and in silico toxicity predictions of its degradation products. RSC Adv. 2015;5(39):31024-38. doi: 10.1039/C5RA01711D.

Lim CK, Lord G. Current developments in LC-MS for pharmaceutical analysis. Biol Pharm Bull. 2002 May;25(5):547-57. doi: 10.1248/bpb.25.547, PMID 12033491.

Meijer J, van den Berg T, Huls R, Hofstede V, Niesing W, van den Beld C. Validation of LC-MS/MS methods for the determination of mirabegron and eight metabolites in human plasma in a paediatric population. J Pharm Biomed Anal. 2019 Apr 15;167:155-60. doi: 10.1016/j.jpba.2019.02.007, PMID 30776753.

Parsha S, Ravindra Kumar YR, Ravichander M, Prakash L, Sudharani B. LC–MS/MS and NMR characterization of forced degradation products of mirabegron. J Liq Chromatogr Relat Technol. 2016;39(4):178-94. doi: 10.1080/10826076.2016.1144201.

Whatley H. Basic principles and modes of capillary electrophoresis. In: Clinical and forensic applications of capillary electrophoresis. Totowa, NJ: Humana Press; 2001. p. 21-58. doi: 10.12691/wjac-1-3-3.

Petersen T, Husted SF. Capillary electrophoresis method for the determination of the β-3 adrenergic receptor agonist mirabegron in pharmaceutical formulations. 2015;207:1-6.

Bose P. The applications of a spectrofluorimeter. AZoM, Vol. 30; 2019.

Morshedy S, Omran G, Abdullatef OA, Omar M, Talaat W. Validated spectrofluorimetric method for determination of mirabegron by utilizing its quenching effect on acetoxymercuric fluorescein reagent. Spectrochim Acta A Mol Biomol Spectrosc. 2020 Oct 5;239:118509. doi: 10.1016/j.saa.2020.118509, PMID 32502818.

Bele AA, Khale A. An overview on thin layer chromatography. Int J Pharm Sci Res. 2011;2:256. doi: 10.13040/IJPSR.0975-8232.2(2).256-67.

YiruGu. Development of quantitative HPTLC-densitometry method for analyzing aminophylline, bisoprolol fumarate, grisiofulrine, hydrochlorothiazide, pyrimethamine, bupropio Hcl, carbamazepine, clomiphene citrate, mirabegron and oxybutynin following a model process developed earlier for transfer of TLC screening method. Curr Top Anal Chem. 2019;11:23-30.

Yehia AM, Sami I, Riad SM, El-Saharty YS. Comparison of two stability-indicating chromatographic methods for the determination of mirabegron in presence of its degradation product. Chromatographia. 2017;80(1):99-107. doi: 10.1007/s10337-016-3210-1.

Sweedler JV. The continued evolution of hyphenated instruments. Anal Bioanal Chem. 2002 Jul;373(6):321-2. doi: 10.1007/s00216-002-1358-z, PMID 12206131.

Shah DA, Tahilramani PJ, Patel VB, Chhalotiya U. High-performance thin-layer chromatographic method for the estimation of mirabegron and solifenacin succinate used in the treatment of overactive bladder syndrome. JPC J Planar Chromatogr Mod TLC. 2019;32(4):323-7. doi: 10.1556/1006.2019.32.4.7.

Chauhan A. Powder XRD technique and its applications in science and technology. J Anal Bioanal Tech. 2014;5(6):1-5. doi: 10.4172/2155-9872.1000212.

Quintana Mendoza JH, Henao JA, Aparicio AP, Romero Bohorquez AR. X-ray powder diffraction data and characterization of mirabegron. Powder Diffr. 2017;32(4):290-4. doi: 10.1017/S0885715617001129.

An JH, Lim C, Kiyonga AN, Chung IH, Lee IK, Mo K. Co-amorphous screening for the solubility enhancement of poorly water-soluble mirabegron and investigation of their intermolecular interactions and dissolution behaviors. Pharmaceutics. 2018 Sep 5;10(3):149. doi: 10.3390/pharmaceutics10030149, PMID 30189645, PMCID PMC6161252.

Chaudhary V, Saxena V. Development of an analytical profile of lamotrigine and its API formulation. Asian J Pharm Clin Res. 2022;15:111-4. doi: 10.22159/ajpcr.2022.v15i1.43396.

Ghante R, Sawant SD, Shinde A, Godse S, Nikam VS. Development and validation of stability-indicating reverse-phase HPLC method for the estimation of ledipasvir in bulk and tablet dosage form. Asian J Pharm Clin Res. 2019;12(3, Mar):326-31. doi: 10.22159/ajpcr.2019.v12i3.30565.

Damle MC, Sonule JA. Hydrolytic degradation study of roxadustat by RP-HPLC and HPTLC. Int J Pharm Pharm Sci. 2023;15:36-49. doi: 10.22159/ijpps.2023v15i8.48355.